New Research Reveals Multiple Naloxone Doses Typically Involved in Successful Opioid Overdose Reversals 

A new study from Hikma Community Health™* showed more than one 4 mg dose of naloxone nasal spray often is involved in an opioid overdose reversal incident.¹ The results of [...]

By |2022-12-05T13:42:13-06:00September 2, 2022|Kloxxado®, Naloxone, News, Research|

Medication Safety With Antidepressants, Anti-anxiety Medications and Prescription Opioids

Antidepressants and anti-anxiety medications can be life-changing treatments for millions of people.1 However, they can have unexpected and potentially risky interactions with other drugs.1,2 Has your doctor prescribed you [...]

By |2022-12-05T13:45:42-06:00January 24, 2022|Kloxxado®, Opioid Overdose, Opioid Safety|

US FDA Approves Kloxxado® (naloxone HCl) Nasal Spray 8 mg to Treat Opioid Overdose

Hikma Pharmaceuticals announced, on April 30, 2021, the US Food and Drug Administration (FDA) approval of Kloxxado® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication. This announcement [...]

By |2022-12-05T13:55:03-06:00October 18, 2021|Kloxxado®, News, Opioid Overdose|
Go to Top

Important Safety Information About KLOXXADO® (naloxone HCl) Nasal Spray 8 mg